CClinicalTrials.gg
Not yet recruitingNCT07769463Updated Aug 18, 2026

Impact of Meditation on Reducing Stress in Glaucoma Patients: An Electronic Feasibility Study

An interventional study of Meditation + Usual Care in Glaucoma, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Glaucoma is a chronic disease that causes loss of vision and potentially blindness as a result of optic nerve damage, often due to increased intraocular pressure. Glaucoma is currently the leading cause of irreversible blindness worldwide.1 In 2020, 4.1 million and 3.6 million adults over the age of 50 suffered from mild to severe glaucoma-induced visual impairment and blindness, respectively.1 However, these figures are likely underestimated since glaucoma can remain asymptomatic until later stages in disease progression.2 The relaxation response evoked by mind-body interventions, such as breathing exercises and meditation, is known to reduce stress and improve quality of life (QOL). In a recent study, mindfulness-based meditation was found to reduce intraocular pressure and improve QOL in patients with glaucoma.3 A feasibility study will be conducted using a mixed-method design to assess the feasibility of the online delivery of meditation for potentially enhancing the QOL and reducing stress in glaucoma patients. Upon recruitment, participants will undergo blocked randomization to either the intervention arm or usual care arm. Participants in each arm will complete online questionnaires at baseline and weeks 1, 3, 6, and 12 to collect data on health-related quality of life (HRQOL), perceived stress, and behaviour using REDCap. REDCap is an online data collection and survey tool hosted by the Office of Research Services of Lawson Research Institute. Our study can help to assess the feasibility of conducting a study on breathing exercises followed by meditation to assess its effects in a sample of patients with glaucoma.

02

Conditions studied

  • Glaucoma

Browse trials for

03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed with glaucoma or suspected to have glaucoma.
  • Aged 65 and above.
  • Able to provide valid informed consent to participate in the research study.
  • Able to read and understand English.
  • No significant self-reported or physician-diagnosed mental health disorder.
  • Independent access to a computer to participate in virtual sessions.
  • Able to sit comfortably for 30 minutes without any major pain or discomfort, can hear well enough to follow verbal instructions when the eyes are closed, and be in good general physical health.
  • Willing to practice meditation at home for \~15 minutes per day.

Exclusion criteria

Exclusion Criteria:

  • Inability to provide valid informed consent.
  • Significant communication barriers or lack of English proficiency that prevents participants from completing the questionnaires.
  • Self-reported substance abuse or dependence within the past 3 months.
  • Having acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months.
  • Having irreversible vision loss that prevents one from completing the questionnaires.
  • Participation in a study involving similar techniques.
  • Established meditation practice, defined as engaging in any formal meditation (e.g., mindfulness, mantra, breath-focused) more than twice per week within the past 3 months.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
158 participants (estimated)

Study arms

  • Other
    Meditation + Usual Care

    Other: Meditation + Usual Care

  • No intervention
    Usual Care

Interventions

  • OtherMeditation + Usual Care

    Meditation is a guided technique that helps to reduce stress, therefore inducing physiological and mental relaxation whilst the eyes are shut.

05

What researchers measure

Primary outcomes

  1. Incidence of Quality of Life as measured by GQOL- 15 in Glaucoma Patients

    HRQoL will be assessed using Glaucoma Quality of Life-15 (GQL-15). GQL-15 is a disease-specific, validated, self-administered questionnaire designed to measure HRQoL in patients with glaucoma. The questionnaire comprises of 15 items on daily functioning across 5 factors: central and near vision (2 items), peripheral vision (6 items), glare and dark adaptation (6 items), and outdoor mobility (1 item). Patients rate these questions on a 5-point Likert scale of difficulty ranging from "1 = no difficulty" to "5 = severe difficulty".

    Time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.

Secondary outcomes

  1. Incidence of Stress as Measured by PSS-10 in Glaucoma Patients

    The Perceived Stress Scale (PSS-10) is a 10-item questionnaire widely used to measure the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes several direct queries about current levels of experienced stress. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. Scores ranging from 0-13 would be considered low stress; scores ranging from 14-26 would be considered moderate stress; and scores ranging from 27-40 would be considered high perceived stress.

    Time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.

  2. Incidence of Behavior as measured by Consideration of Future Consequences - 14 (CFC-14) in Glaucoma Patients

    In previous research, consideration of future consequences (CFC) has been recognized as a critical factor influencing individuals' engagement in health-promoting behaviors. Strathman et al. initially developed a 12-item unidimensional Consideration of Future Consequences (CFC) scale to measure individual differences in temporal orientation. This scale assesses the degree to which individuals consider the potential impact of their current behavior on immediate or distant outcomes.38 Low CFC scores indicate that individuals are more inclined to pursue immediate rewards, whereas high scores are observed among individuals who prioritize future advantages and sacrifice immediate gratification.

    Time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07769463
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Responsible party
Sponsor
First posted
Aug 18, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Aug 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion